Claris Biotherapeutics
Jersey City
About Claris Biotherapeutics
Claris Biotherapeutics develops a topical formulation intended to cure corneal wounds, ulcers, and scars. The formulation creates a recombinant hepatocyte growth factor which accelerates the healing process, providing healthcare providers noninvasive therapeutic treatment.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $107.1M
- Funding stage: Early Stage Venture
- Last round: Debt Financing (Mar 2025)
- Website: clarisbio.com
Industries & Categories
Biotechnology, Health Care, Therapeutics
Canonical: https://fsome.com/organization/claris-biotherapeutics-36086 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.